We are live on ! Find out more
FOMX

Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX

Delisted

FOMX was delisted on the 6th of March, 2020.

45 hedge funds and large institutions have $120M invested in Foamix Pharmaceuticals Ltd. Ordinary Shares in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

17% more capital invested

Capital invested by funds: $102M → $120M (+$17.7M)

0% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 12

0% more call options, than puts

Call options by funds: $1K | Put options by funds: $1K

20% less funds holding

Funds holding: 5645 (-11)

73% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 15

Holders
45
Holders Change
-11
Holders Change %
-19.64%
% of All Funds
1.12%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
4
Increased
12
Reduced
12
Closed
15
Calls
$1K
Puts
$1K
Net Calls
Net Calls Change
+$197K
Name Holding Trade Value Shares
Change
Change in
Stake
Susquehanna International Group
51
Susquehanna International Group
Pennsylvania
-$78K -16,887 Closed
D.E. Shaw & Co
52
D.E. Shaw & Co
New York
-$76K -16,327 Closed
IIA
53
IPG Investment Advisors
California
-$67.6K -14,575 Closed
Group One Trading
54
Group One Trading
Illinois
-$64K -13,791 Closed
TRCT
55
Tower Research Capital (TRC)
New York
-$23K -4,872 Closed
Creative Planning
56
Creative Planning
Kansas
-$14K -3,000 Closed
SCM
57
Stonepine Capital Management
Oregon
-$13K -2,878 Closed
Barclays
58
Barclays
United Kingdom
-$1K -149 Closed
Royal Bank of Canada
59
Royal Bank of Canada
Ontario, Canada
+$15 +3 New

FOMX Hedge Fund Activity: Q3 2017 in Review

45 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) for Q3 2017, worth a combined $120M — up 17% from $102M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of FOMX and 4 opened new positions — a net loss of 11 holders — while 12 trimmed existing stakes and 12 added.

The largest buyer was Millennium Management, adding an estimated $3.03M. The largest seller was Folger Hill Asset Management, exiting entirely with an estimated $2.1M sold.

  • 45 institutional investors held Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) as of Q3 2017, down from 56 in Q2 2017.
  • Funds reported $120M of Foamix Pharmaceuticals Ltd. Ordinary Shares stock for Q3 2017, up 17% quarter-over-quarter.
  • 4 funds opened new Foamix Pharmaceuticals Ltd. Ordinary Shares positions in Q3 2017 and 15 closed out, a net change of -11 holders.
  • The largest Foamix Pharmaceuticals Ltd. Ordinary Shares buyer in Q3 2017 was Millennium Management, an estimated $3.03M added.
  • The largest Foamix Pharmaceuticals Ltd. Ordinary Shares seller in Q3 2017 was Folger Hill Asset Management, an estimated $2.1M sold.

Based on aggregated 13F filings for Q3 2017.